Recombinant proteins have emerged as powerful tools for scientific research, drug development, and industrial applications. By harnessing the principles of genetic engineering, scientists can produce these proteins in large quantities with enhanced efficiency and precision. This article aims to provide an overview of recombinant proteins, their significance, and the expression systems used to produce them.

Fig 1. Steps for synthesis of the recombinant proteins in E. coli (Saigo, 2013)

What are Recombinant Proteins?

Recombinant proteins are proteins that are generated by introducing specific DNA sequences encoding the desired protein into a host organism, typically a bacterium, yeast, or mammalian cell line. The process involves isolating the gene of interest, modifying it as necessary, and introducing it into the host organism's genome. Once incorporated, the host cell utilizes its machinery to transcribe and translate the introduced DNA, producing the recombinant protein of interest.

Comparison of Recombinant Proteins and Natural Proteins

Recombinant proteins, produced through genetic engineering techniques, and natural proteins, synthesized within living organisms, possess distinct characteristics. Here is a comparison of some key features of recombinant proteins and natural proteins:

• Source

Recombinant proteins are produced using recombinant DNA technology in host organisms such as bacteria, yeast, mammalian cells, or insect cells. The genetic information for the protein of interest is introduced into these organisms, which then produce the protein.

Natural proteins are synthesized within living organisms through the process of transcription and translation, following the expression of the respective genes in the organism's genome.

• Structure and Function

Recombinant proteins generally have the same amino acid sequence as their natural counterparts, ensuring similar primary structures. However, their higher-order structures (secondary, tertiary, and quaternary structures) may differ due to variations in the production environment. As a result, recombinant proteins may exhibit altered folding patterns or modified functionalities compared to their natural counterparts.

Natural proteins have evolved within specific organisms, allowing them to adopt their native structures and perform their intended biological functions with high efficiency. They possess precise folding patterns critical for their proper functioning, and their structures are optimized through evolution.

• Post-translational Modifications

The extent and types of post-translational modifications (PTMs) in recombinant proteins depend on the production system used. Bacterial expression systems typically lack complex PTMs, such as glycosylation or phosphorylation. In contrast, eukaryotic expression systems, including yeast, mammalian cells, and insect cells, can perform various PTMs, enabling the production of recombinant proteins with more authentic modifications.

Natural proteins undergo a wide array of PTMs, including glycosylation, phosphorylation, acetylation, methylation, and others. These modifications are crucial for their stability, activity, cellular localization, and interactions with other molecules.

• Purity and Contaminants

Recombinant protein production processes often involve purification steps to isolate the protein of interest from the host organism's cellular components and contaminants. However, depending on the production system and downstream purification techniques, recombinant proteins may contain impurities, such as residual host cell proteins, nucleic acids, or other contaminants. Efforts are made to minimize these impurities through purification and quality control procedures.

Natural proteins synthesized within living organisms undergo natural purification processes within the cell. They are less prone to contamination from host cell components, making them generally purer compared to recombinant proteins.

• Scalability and Production Costs

Recombinant protein production can be scaled up to generate large quantities of proteins. Bacterial expression systems, in particular, offer high yields and cost-effective production. However, for more complex proteins requiring authentic post-translational modifications, production costs can be higher due to the need for eukaryotic expression systems or additional purification steps.

Natural proteins are produced within the organism's natural cellular environment, and their production scales are limited to the organism's growth and metabolism. Large-scale production of natural proteins often requires complex cultivation and extraction processes, making them more costly compared to recombinant protein production.

Recombinant Protein Production Systems

Recombinant proteins are proteins that are produced using genetic engineering techniques, where the DNA encoding the protein of interest is introduced into a host organism to enable its production. Here are the main methods used to produce recombinant proteins:

Table 1. Comparison of different recombinant protein expression systems (Pratheesh, 2015)

• Bacterial Expression Systems

Bacterial expression systems, such as Escherichia coli (E. coli), are among the most commonly employed systems for recombinant protein production. They offer rapid growth, ease of genetic manipulation, and cost-effectiveness. Researchers can introduce the gene of interest into a plasmid vector, which is then transformed into bacteria. Upon induction, the bacterial machinery reads the gene and produces the desired protein.

E. coli is especially well-suited for producing small to medium-sized proteins with simple post-translational modifications. However, it may not be ideal for expressing eukaryotic proteins requiring complex post-translational modifications, such as glycosylation or disulfide bond formation. Moreover, inclusion bodies, which are often formed in E. coli, can complicate protein purification and may require additional refolding steps.

• Yeast Expression Systems

Yeast expression systems, like Saccharomyces cerevisiae, offer both prokaryotic and eukaryotic features, making them versatile for a wide range of proteins. Yeasts can perform certain post-translational modifications, such as glycosylation, disulfide bond formation, and folding, which are essential for some eukaryotic proteins' functionality. Additionally, yeast systems are scalable and relatively cost-effective.

S. cerevisiae is commonly used for industrial-scale production of recombinant proteins, enzymes, and vaccines. It offers a well-established and efficient system for protein production. However, it may not be suitable for expressing highly complex and heavily glycosylated proteins, as its glycosylation pattern differs from that of mammalian cells.

• Insect Cell Expression Systems

Insect cell expression systems, particularly based on the baculovirus-insect cell expression platform, are valuable for producing complex eukaryotic proteins. Baculovirus vectors efficiently infect insect cells, such as Spodoptera frugiperda (Sf9) or Trichoplusia ni (High Five), allowing high expression levels and proper post-translational modifications.

The baculovirus-insect cell system is widely used for expressing bioactive proteins like vaccines, therapeutic antibodies, and enzymes. Insect cells can perform many eukaryotic post-translational modifications, making them suitable for expressing proteins with enhanced bioactivity. Additionally, the system offers a higher yield compared to bacterial or yeast systems. However, insect cells may not always produce human-like glycosylation patterns, which could impact the protein's functionality.

• Mammalian Cell Expression Systems

Mammalian cell expression systems, often using Chinese hamster ovary (CHO) cells, are considered the gold standard for producing biopharmaceuticals. Mammalian cells possess the machinery for complex post-translational modifications, including proper folding, glycosylation, and phosphorylation. These systems yield proteins with enhanced bioactivity and safety profiles, particularly for human therapeutic applications.

CHO cells are widely used in the biopharmaceutical industry due to their ability to perform human-like glycosylation, ensuring the produced protein's compatibility with human systems. However, mammalian cell expression systems are expensive, require specialized facilities, and have longer production timelines compared to other systems.

• Plant Cell Expression Systems

Plant cell expression systems, involving plants like tobacco or rice, offer an interesting alternative for recombinant protein production. They are cost-effective, easily scalable, and provide proper eukaryotic post-translational modifications. Additionally, plant-based expression systems have shown promise in producing vaccines and biopharmaceuticals.

Plants can perform complex post-translational modifications, similar to mammalian cells, which can be advantageous for certain proteins' functionality. Furthermore, plants do not harbor human pathogens, reducing safety concerns associated with using mammalian systems. However, downstream purification can be challenging due to the presence of plant-specific contaminants.

• Unicellular Microalgae Systems

Unicellular microalgae systems have emerged as a novel expression platform for producing recombinant proteins. Microalgae, like Chlamydomonas reinhardtii, can be genetically engineered to express target proteins efficiently. They offer a photosynthetic advantage, reducing the dependence on expensive growth media. Although research in this area is relatively new, microalgae systems hold great potential for sustainable and low-cost protein production.

Microalgae can perform eukaryotic post-translational modifications and produce complex proteins. They have the potential to produce high-value proteins, including enzymes, bioactive peptides, and vaccine antigens. However, challenges related to scaling up production and optimizing expression levels still need to be addressed.

• Cell-free Systems

Cell-free expression systems offer a unique approach where proteins are produced outside intact cells. These systems utilize cellular extracts containing the necessary transcription and translation machinery to synthesize proteins from DNA templates. Cell-free systems are rapid, flexible, and amenable to high-throughput applications. They can express toxic or membrane proteins that might be challenging in living cells.

Cell-free systems have gained popularity in recent years due to their ability to quickly produce proteins without the need for cell culture. Additionally, they can be customized for specific needs, such as incorporating non-natural amino acids or modifying translation rates. However, certain post-translational modifications may be absent in cell-free systems, limiting their applicability for certain protein types.

Conclusion

The ability to produce recombinant proteins has revolutionized various scientific and industrial fields, enabling researchers to study and manipulate proteins that were previously scarce or challenging to obtain. Recombinant proteins find diverse applications, from serving as therapeutic agents, vaccines, and enzymes in medicine, to being utilized as tools in molecular biology and biotechnology research. The choice of a recombinant protein expression system depends on several factors, including the protein of interest, desired post-translational modifications, scale of production, and downstream processing requirements. Each of these systems has its strengths and limitations, making them suitable for specific applications in recombinant protein production. With ongoing advancements in genetic engineering and biotechnology, recombinant proteins continue to drive innovation, promising exciting possibilities in medicine, agriculture, and various other domains.

References

1. Saigo, Mariana, et al. "Biochemical approaches to C 4 photosynthesis evolution studies: the case of malic enzymes decarboxylases." Photosynthesis research 117 (2013): 177-187.
2. Pratheesh, P. T., and M. Vineetha. "Genetic engineering of microalgae for production of therapeutic proteins." Handbook of Marine Microalgae. Academic Press, 2015. 415-427.

All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.